CKPT's logo.
Ticker Symbol: CKPT

Checkpoint Therapeutics Inc

$3.80 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001651407

Company Profile

Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma intended to support one or more applications for marketing approval. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor ('EGFR') inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 2 Gansevoort St Fl 9
CEO: N/A
Tags:
  • Health Technology
  • Pharmaceuticals: Major

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $2.16
Change: $0.19 ( 9.64%)
Days Range: $1.86 - $2.22
Beta: 1.54
52wk. High: $10.19
52wk. Low: $1.30
Ytd. Change -51.80%
50 Day Moving Average: $1.82
200 Day Moving Average: $2.44
Shares Outstanding: 20893485

Valuation

Market Cap: 4.5B
PE Ratio: -0.42
EPS (TTM): -5.15

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A